Modulation of vascular endothelium by imatinib: a study on the EA.hy 926 endothelial cell line

J Chemother. 2006 Feb;18(1):56-65. doi: 10.1179/joc.2006.18.1.56.

Abstract

In this study the EA.hy 926 endothelial cell line--simulating endothelial cells--was treated with imatinib in order to define a possible anti-angiogenic role for imatinib. Dose and time response experiments were performed. Cell morphology was studied, while migration efficiency, intercellular permeability and VE-cadherin expression were assayed, both in the presence and in the absence of imatinib. Imatinib-induced EA.hy 926 cell apoptosis was also examined. Results showed that imatinib reduced the endothelial cell population, changed cell monolayer morphology and reduced cell-to-cell cohesiveness. Migration efficiency was significantly decreased while intercellular permeability was 2.76-fold increased in the presence of imatinib. Indirect immunofluorescence microscopy showed nearly complete down-regulation of VE cadherin in imatinib-treated cells. Furthermore, apoptotic activity was detected in imatinib-treated cells. Altogether our results support an antiangiogenic profile for imatinib that possibly contributes to its therapeutic potential.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Benzamides
  • Cadherins / metabolism
  • Cell Movement / drug effects
  • Cells, Cultured
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Fluorescent Antibody Technique, Indirect
  • Humans
  • Imatinib Mesylate
  • Neovascularization, Physiologic
  • Piperazines / pharmacology*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / pharmacology*
  • Receptor, Platelet-Derived Growth Factor alpha / metabolism
  • Receptor, Platelet-Derived Growth Factor beta / metabolism

Substances

  • Antigens, CD
  • Antineoplastic Agents
  • Benzamides
  • Cadherins
  • Piperazines
  • Pyrimidines
  • cadherin 5
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Receptor, Platelet-Derived Growth Factor alpha
  • Receptor, Platelet-Derived Growth Factor beta